Provention Bio to Present at the Stifel Virtual Healthcare Conference

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) announced its participation in the Stifel Virtual Healthcare Conference on November 18, 2020, at 8:00 am E.T. During the event, management will present their innovative biopharmaceutical strategies focused on preventing autoimmune diseases. The company has submitted a Biologics License Application (BLA) for its lead drug candidate, teplizumab, aimed at delaying or preventing clinical type 1 diabetes in at-risk individuals. A webcast of the presentation will be accessible on the company's website and archived for 90 days.

News Market Reaction – PRVB

+5.46%

+5.46% Session move

In the trading session that priced this news, PRVB gained 5.46%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020, at 8:00 am E.T.

A webcast of the presentation can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 90 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company has submitted a BLA to the FDA for its lead investigational drug candidate, teplizumab, for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals. The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.proventionbio.com for more information or follow us on Twitter: @Proventiobio

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:
Sam Martin, Argot Partners
sam@argotpartners.com   
212-600-1902

Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-stifel-virtual-healthcare-conference-301170677.html

SOURCE Provention Bio, Inc.

FAQ

When is Provention Bio presenting at the Stifel Virtual Healthcare Conference?

Provention Bio will present on November 18, 2020, at 8:00 am E.T.

What is Provention Bio's lead investigational drug candidate?

Provention Bio's lead investigational drug candidate is teplizumab.

What disease is teplizumab targeting?

Teplizumab is targeting the delay or prevention of clinical type 1 diabetes.

Where can I access the presentation webcast by Provention Bio?

The webcast will be available on Provention Bio's website in the Events and Webcasts section.

What has Provention Bio submitted to the FDA?

Provention Bio has submitted a Biologics License Application (BLA) for teplizumab.